Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Parkinson's Disease, Dyskinesias, Movement Disorders

In brief

The primary objective of this study is to evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

Key facts

Study ID: NCT02589340
Run by: Oregon Health and Science University
People needed: 6
Starts: 2016-01-01
Expected to finish: 2021-02-23
Last updated by the study team: 2021-03-05

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Parkinson's disease diagnosis
Currently taking a levodopa containing medication for Parkinson's disease
Mild to Severe dyskinesia
Currently taking between 200-500 mg of amantadine daily for treatment of levodopa-induced dyskinesia with insufficient suppression levodopa-induced dyskinesia.
Stable medication regimen for at least 4 weeks prior to study.

You may not qualify if…

Currently receiving any other treatment for levodopa-induced dyskinesia, including but not exclusive to deep brain stimulation.
Not able to follow verbal commands
Not able to stand unsupported for at least 60 seconds
Not able to answer a patient questionnaire about their symptoms of Parkinson's disease and dyskinesia.
Have proprioceptive deficits.
Have a history of hepatic impairment
Currently have severe renal impairment
Currently have any other medical or psychiatric diagnosis that would preclude their ability to safely participate in the study.
Significant cognitive impairment
Pregnancy
Breast-Feeding
Unable to swallow study drug (capsule)

Where it is running

VA Portland Health Care System — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.